TrialNeuro-oncology2024

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.

Isabel Arrillaga-Romany et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.